Enovis: Valuation Is Too Low, But Needs To Differentiate On Growth

2026-02-12 06:00:00 ET

Smaller med-tech can be a value trap until and unless it distinguishes itself on growth; as a former sell-side med-tech analyst, I can tell you that there are many institutions that won’t even consider a smaller med-tech if it’s not growing at a double-digit rate (often 20%+). That’s an ongoing problem for Enovis ( ENOV ), as the market just doesn’t seem to care about this company so long as revenue growth remains stuck in the mid-single-digits and free cash flow generation is marginal at best....

Read the full article on Seeking Alpha

For further details see: